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Atherogenic ω-6 lipids are physiological ligands of peroxisome proliferator-activated receptors (PPARs) and elicit pro- and
antiatherogenic responses in vascular cells. The objective of this study was to investigate if ω-6 lipids modulated the early growth
response-1 (Egr-1)/PPAR crosstalk thereby altering vascular function. Rat aortic smooth muscle cells (RASMCs) were exposed to
ω-6 lipids, linoleic acid (LA), or its oxidized form, 13-HPODE (OxLA) in the presence or absence of a PPARα antagonist (MK886)
or PPARγ antagonist (GW9662) or PPAR-speciﬁc siRNA. Our results demonstrate that ω-6 lipids, induced Egr-1 and monocyte
chemotactic protein-1 (MCP-1) mRNA and protein levels at the acute phase (1–4hrs) when PPARα was downregulated and at
subacute phase (4–12hrs) by modulating PPARγ, thus resulting in altered monocyte adhesion to RASMCs. We provide novel
insights into the mechanism of action of ω-6 lipids on Egr-1/PPAR interactions in vascular cells and their potential in altering
vascular function.
1.Introduction
Early growth-response (Egr-1) is a critical mediator of
vascular pathology by activating its dependent genes, tumor
necrosis factor-α (TNFα) (a potential stimulator of nuclear
factor kappa B-NFκB) and monocyte chemotactic protein-1
(MCP-1) [1–4]. MCP-1 has a speciﬁc Egr-1 binding element
in its promoter region and is therefore directly activated by
Egr-1 [5, 6]. Many of these target genes in turn activate
Egr-1 by a positive feedback mechanism and thereby further
amplifying their eﬀects [7].
Peroxisome proliferator-activated receptors (PPARα, β,
γ) are transcription factors that regulate various cellular
processes including lipid and glucose homeostasis [8, 9].
Both PPARα and PPARγ are expressed in vascular cells in-
cluding endothelial cells, smooth muscle cells (vSMCs), and
monocyte/macrophages [10, 11]. Activators of PPARs have
beneﬁcial eﬀects against atherosclerosis [12, 13]. Ligand-
mediatedactivationofPPARα[14–17]andPP ARγ attenuates
the release of inﬂammatory factors including the production
of monocyte chemotactic protein-1 [18, 19]. Interestingly,
PPARs can directly interact with Egr-1 and attenuate its
downstream eﬀects [20]. This attenuation is eﬀective by
the activation of both PPAR isotypes, PPARα [21]a n d
PPARγ [22]. However, in vascular cells there exists a time-
dependent crosstalk between Egr-1 and PPARs, for example,
Egr-1 exhibits a critical early stimulatory eﬀect but a later
inhibitory eﬀect on PPARs [23].
Atherogenic ω-6 lipids such as linoleic acid (LA, 18:2n−
6) and its oxidized forms, 13-hydroperoxy octadecadienoic
acid (13-HPODE) and 13-hydroxyoctadecadienoic acid (13-
HODE) are physiological ligands for both PPARα [24]a n d
PPARγ [25–28], that can covalently interact with PPARs and
alter their activity [29, 30]. The biological signiﬁcance of
these interactions is not well understood. LA is the pre-
dominant polyunsaturated fatty acid found in the Western
diet [31], which at lower doses has lipid-lowering beneﬁcial
eﬀects [32], but, deleterious eﬀects when consumed in excess
[33]. Oxidized forms of LA (oxidized linoleic acid (OxLA))
and other oxidized ω-6 lipids are present in signiﬁcant
amounts in heated oils and processed foods [34–37]. ω-6
lipids are also major components of oxidized low-density2 PPAR Research
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Scheme 1: Atherogenic ω-6 lipids modulate PPAR-Egr-1 crosstalk.
A schematic representation of a possible mechanism by which ω-
6 lipids and their oxidized forms regulate PPAR-Egr-1 crosstalk in
a time-mediated fashion and thereby altering smooth muscle cell
function. ω-6 lipids seemed to have a time-dependent modulation
of PPAR isotypes, PPARα at acute phase and PPARγ at subacute
phase. This modulation of PPAR isotype altered the ability of
these lipids to exert an antiatherogenic eﬀects via PPARs or
proatherogenic eﬀects via Egr-1.
lipoproteins (Ox-LDLs) that exhibit both pro- and anti-
atherogenic eﬀects on vascular cells [38–40].
Since Egr-1 regulates the proinﬂammatory and PPARs
regulates the anti-inﬂammatory pathways in vascular cells,
and that atherogenic ω-6 lipids interact with both these
transcription factors, we speculate that these lipids could
inﬂuence the crosstalk between these two transcription
factors in a time- and concentration-dependent manner
(Scheme 1) and thereby inﬂuence atherogenic events. In
this study, the ability of LA and OxLA (ω-6 lipids that
are abundant in dietary sources and OxLDL) to inﬂuence
Egr-1 and PPAR crosstalk was investigated in primary rat
aortic smooth muscle cells (RASMCs) in the presence or
absence of known PPAR antagonists or by knocking down
PPARs by siRNA approach. To our knowledge this is the
ﬁrst study that has investigated the ability of atherogenic ω-
6 lipids to modulate EGR-1-PPAR crosstalk. Our ﬁndings
will provide insights into the biological signiﬁcance of the
interactions between physiological ligands of PPAR and
other transcription factors.
2.MaterialsandMethods
2.1. Materials. Dimethylsulfoxide (DMSO), PPARγ antag-
onist (GW9662) was obtained from Invitrogen (Carlsbad,
CA). PPARα antagonist (MK886) was obtained from Cay-
man (Ann Arbor, MI). Linoleic acid and soybean lipoxidase
were obtained from Sigma (St. Louis, MO). Rabbit Egr-1
and MCP-1 monoclonal antibody was obtained from Abcam
(Cambridge, MA). Rabbit anti-actin monoclonal antibody
was obtained from Sigma (St. Louis, MO). PPRE-luciferase
construct [p(AOX3)-TKSL] was a gift (Dr. Richard Niles,
Marshall University, Huntington, WV).
2.2. Oxidation of Linoleic Acid. A 10mM stock solution of
linoleicacid(LA-18:2)wasﬁrstpreparedinabsoluteethanol
whichwasfurtherdilutedinphosphate-buﬀeredsaline(PBS)
to make 0.1mM LA solution. A fresh aliquot of 0.1mM
LA solution was oxidized with soybean lipoxidase (100–
200U/100nmol, 1hr at 37◦C) to generate oxidized linoleic
acid (OxLA-13-HPODE and 13-HODE) [41]. The conver-
sion of LA to OxLA (HPODE or HODE) was monitored
spectrophotometrically (Shimadzu, Columbia, MD) as an
increase in the absorbance at optical density of 234nm.
Usually, >98% of unoxidized LA was converted to OxLA.
2.3. Cell Treatment and Sample Collection. Primary rat aortic
smooth muscle cells (RASMCs) were cultured in speciﬁc
growth media following the recommendations of the manu-
facturer(ATCC,Manassas,VA)andusedatapassagenumber
below15.Unlessotherwiseindicated,70–80%quiescentcells
were ﬁrst pretreated with GW9662 (1μM), MK886 (10μM)
or DMSO (1μM) (vehicle) for 2 hours. Pretreated cells
were then exposed to either LA or OxLA at 10, 25 and
50μMc o n c e n t r a t i o n s ,f o r0 ,1 ,4 ,o r1 2h o u r s( h r s ) .T h e
control(CTRL)wasdeﬁnedascellstreatedwithvehiclealone
(DMSO). Each treatment was run in duplicates and one set
of cells were used for qRT-PCR analyses and the second set
wasusedforWesternblotting.Eachexperimentwasrepeated
at least three times.
2.4. siRNA Transfection. RASMCs were cultured to 50–70%
conﬂuence and then transfected using 50nmoles of a pooled
mixture of ON-TARGETplus SMARTpool siRNA duplexes
(SMARTpool,ThermoScientiﬁcDharmacon,Lafayette,CO)
for PPARα,P P A R γ or a nonspeciﬁc control siRNA (Nontar-
geting pool, Thermo Scientiﬁc Dharmacon, Lafayette, CO)
using Thermo Scientiﬁc DharmaFECT transfection reagents
and siRNA transfection protocol (Thermo Scientiﬁc Dhar-
macon, Lafayette, CO). Forty eight hours after transfection,
quiesced cells were treated with vehicle (CTRL), 25 and
50μM LA, and 10, 25 and 50μM OxLA for either 4 or
12 hours. Egr-1 mRNA levels were determined after each
treatment by real-time PCR.
2.5. Quantitative Real-Time Reverse-Transcriptase PCR (qRT-
PCR). Total RNA was extracted from the treated cells
using the TRIzol reagent kit (Sigma, St-Louis, MO) ac-
cording to the manufacturer’s protocol. The mRNA lev-
els of Egr-1 and MCP-1 were analyzed in a MyiQ real
time PCR system (Bio-Rad, Hercules, CA). β-actin was
used as the house-keeping gene. The real-time PCR was
carried out in 25μLo faS Y B Rg r e e nr e a c t i o nm i x -
ture containing 1μL of cDNA and iQ SYBR Green Su-
permix (Bio-Rad, Hercules, CA) containing the respec-
tive primers: Egr-1 (NM 012551) 5 -aacactttgtggcctgaacc-
3 ,3  -aggcagaggaagacgatgaa-5 ; MCP-1 (NM 031530) 5 -
atgcagttaatgccccactc-3 ,3  -ttccttattggggtcagcac-5 ; β-actin
was used as the house-keeping control (NM 031144)
5 -gtccacccgcgagtacaacct-3 ,3  -tcgacgacgagcgcagcgata-5 .A
sequence detection program calculated a threshold cycle
number (CT) at which the probe cleavage-generated ﬂu-
orescence exceeded the background signal [42]. The real-
time PCR results were expressed as fold change ± Standard
Error of ΔCt for each group compared to control (vehiclePPAR Research 3
treatment) after normalizing to beta actin (housekeeping
gene) using the Pfaﬄ method (2−ΔΔCt)[ 42].
2.6. Western Blot Analysis. For Western blotting, the treated
cells were rinsed in phenol-red free Hanks buﬀer and whole
cell lysates were prepared in RIPA buﬀer (TRIS 50mM,
sodium chloride 150mM, Triton 1%, sodium deoxycholate
1%, SDS 0.1%, EDTA 5 mM) containing protease inhibitors
(Roche Diagnostics, Indianapolis, IN). Total protein in the
cell lysates was quantiﬁed using the Lowry method [43].
Equal amount of the cell proteins were subjected to SDS-
PAGE. After transfer, blots were probed individually with
a solution of rabbit antibody to rat Egr-1 (1:3000), MCP-
1 (1:7000), PPARα (1:2000), PPARγ (1:7000), or β-actin
(1:1000) as housekeeping protein and then analyzed using
the chemiluminescence detection method (Millipore, Biller-
ica, MA). The protein levels were quantiﬁed by densitometry
of the respective bands on the autoradiograph (Bio-Rad,
Hercules, CA). The results were expressed as the ratio of
p r o t e i nl e v e l si nt r e a t e ds a m p l e sc o m p a r e dt oC T R La f t e r
normalizing to β-actin.
2.7. Transient Transfection and Luciferase Reporter Assay.
RASMCs in 12-well plates (50,000 cells per well) were trans-
fected with 0.5μg per well of the PPRE-luciferase construct
(p(A-OX3)-TKSL) using Lipofectamine-2000 transfection
reagent (Promega, Madison, WI). After 24hrs of transfec-
tion, cells were transferred to serum-free EMEM media con-
taining 1% charcoal stripped fetal bovine serum and either
pretreated or untreated with PPAR antagonists, [MK886
(10μM) or GW9662 (1μM)]. Following pretreatment, the
c e l l sw e r ee x p o s e df o r4h r sw i t he i t h e rL Ao rO x L Aa t1 0 ,
25, 50μM concentrations. Controls (CTRL) were deﬁned as
samples without LA or OxLA treatment. At the end of lipid
treatment, the cells were washed in PBS three times and
solubilizedin1Xlysisbuﬀer(Roche,Indianapolis,IN).PPRE
transactivity was determined in the cell lysates by assaying
for ﬁreﬂy luciferase activities using the Luciferase Reporter
Assay System (Berthold, Germany). Each experiment was
performedinduplicatesandrepeatedthreetimes.Theresults
were expressed as the ratio of relative luciferase units (RLU)
in treated samples/CTRL values.
2.8. Monocyte Adhesion Assay. To demonstrate the physio-
logical consequences of alterations in Egr-1/MCP-1 levels
by ω-6 lipids on vascular function, monocyte adhesion
studies were performed using established protocols [44].
Brieﬂy, RASMCs were seeded in 12-well plates at a cell
density of 1 × 105 cells/well. Once the cells reached 70–
80% conﬂuence, it was exposed to 10–50μM concentrations
of LA or OxLA with or without pretreatment to PPAR
antagonists, MK886 (10μM) or GW9662 (1μM). At the end
of 4 or 12 hours of lipid treatment, RASMCs were rinsed
with Hanks balanced salt solution (HBSS) followed by the
addition of 5 × 104 cells/cm2 THP1 (human monocytes)
to each well. After 24hrs coculture of RASMC and THP1,
the plates were rinsed three times with PBS and adhered
monocytes were counted in a 3 × 3 ﬁeld under an inverted
microscope (Leica-DMI4000B, Wetzlar, Germany) for each
condition and duration of treatment. The average number
of adhered monocytes for each treatment and time duration
were counted by two independent investigators.
2.9. Statistical Analysis. The real-time PCR results were ex-
pressed as fold change ± Standard Error of ΔCt for each
group compared to control using the Pfaﬄ method (2−ΔΔCt)
[42].AllstatisticswereperformedattheΔCtstageinorderto
exclude potential bias due to averaging of data transformed
through the equation 2∧−(ΔΔCt)[45]. One way ANOVA was
usedforthecomparisonbetweentwotreatmentsateachtime
point. Vehicle control of the baseline (no antagonist pre-
treatment) group was used as the control for all statistical
comparisons. Diﬀerences due to treatments in the density
of the protein bands after Western blotting and the number
of attached THP1 monocytes were analyzed for signiﬁcance
by one-way ANOVA, compared to the untreated, vehicle
control. The relative data was presented as mean ± Standard
Error of mean. Signiﬁcance was conﬁrmed using post hoc
analysis using Fisher’s least signiﬁcant diﬀerence (Fisher’s
LSD) test. A P<0.05 was considered statistically signiﬁcant.
In the ﬁgures, signiﬁcant diﬀerences between vehicle control
and treated samples is indicated as an asterisk-∗,w h e r e a s
significant diﬀerence between the lowest concentration to
higher concentrations of the lipid treatments is indicated as
“#”.
3. Results
3.1. ω-6 Lipids Modulate PPAR Protein Levels and Transac-
tivity. PPARs are transcription factors, which upon ligand
activation, promote regulation of genes that exhibit PPAR
response elements [46, 47]. The PPAR ligands regulate these
transcription factors at the protein level. In RASMCs, LA
and OxLA had a diﬀerential induction of PPAR subtypes,
with an induction of PPARα protein in the acute phase (1–
4hrs)(Figure 1(a)) and induction of PPARγ at the subacute
phase (12hrs) (Figure 1(b)) compared to vehicle CTRL.
The OxLA at increasing concentrations had 2–4-fold higher
induction of PPARα protein at 4hrs but less than baseline
levels at 12hrs. In contrast, OxLA was less eﬀective on
PPARγ protein, with an induction of only about 2-fold at
12hrs.
PPAR transactivity studies using RASMCs transfected
with PPRE-luciferase constructs showed that compared to
vehicle CTRL, both LA and OxLA induced PPRE transac-
tivity in a concentration-dependent manner, (Figure 1(c)).
Pretreatment of the cells with a PPARα antagonist MK886,
exhibited a signiﬁcant attenuation of the PPRE activity
that was induced at all concentrations of LA and OxLA
(−81% for LA and −50–80% for OxLA) (P<0.005)
after 4hrs treatment. On the contrary, pretreatment with
PPARγ antagonist, GW9662 only partially inhibited the
PPRE transactivity induced by LA and OxLA (−17% for LA
and −3–17% for OxLA), (Figure 1(c)). These results suggest
a time-dependent modulation of PPAR subtypes by ω-6
lipids.4 PPAR Research
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Figure 1: ω-6 lipids modulate PPAR protein levels and PPRE transactivity in a time-dependent manner. Western blotting of RASMC lysates
treatedwith10–50μMofLAandOxLAfor0–12hrsusingPPARαandPPARγ antibodyshowsinductionofPPARαatacutephaseandPPARγ
at subacute phase. Control (CTRL) was deﬁned as the cells treated with vehicle only. The results were expressed as mean ± SEM (Standard
Error of Mean) deﬁned by the ratio of protein levels in treated samples compared to CTRL. All data were normalized to β-actin (house-
keeping protein) (a) PPARα protein levels after 1hr, 4hr, 12hrs treatment. (b) PPARγ protein levels after 1hr, 4hr, 12hrs treatment. The
ﬁgure is a representation of three independent blots. One way ANOVA was used for the comparison between two treatments. Signiﬁcance
was conﬁrmed using post hoc analysis using Fisher LSD test. ∗P< 0.05. (c) PPAR transactivity was measured in PPRE-luciferase transfected
RASMCs which were pretreated with 10μM MK886 (PPARα antagonist) or 1μM GW9662 (PPARγ antagonist) followed by exposure to
10–50μM LA or OxLA for 4hrs. The assay were run in duplicates and repeated three independent times. The results were expressed as
mean relative luciferase activity ± SEM (Standard Error of Mean). One way ANOVA was used for the comparison between two treatments.
SigniﬁcancewasconﬁrmedusingposthocanalysisusingFisherLSDtest. ∗comparedtoCTRL,P< 0.05; #comparedto10μMconcentration,
P< 0.05.PPAR Research 5
0
3
6
9
F
o
l
d
c
h
a
n
g
e
F
o
l
d
c
h
a
n
g
e
F
o
l
d
c
h
a
n
g
e
1hr
Egr-1
0
6
12
4hrs
30
60
90
∗∗∗
∗∗∗
∗∗
∗∗
∗∗
∗
∗
∗
∗∗
∗
∗
##
##
##
##
##
##
0
2
4
6
12hrs
10
15 #
# #
#
15
20
Baseline GW9662 MK886
Baseline GW9662 MK886
Baseline GW9662 MK886
CTRL
LA 10 (μM)
LA 25 (μM)
LA 50 (μM)
OxLA 10 (μM)
OxLA 25 (μM)
OxLA 50 (μM)
∗
(a)
CTRL
LA 10 (μM)
LA 25 (μM)
LA 50 (μM)
OxLA 10 (μM)
OxLA 25 (μM)
OxLA 50 (μM)
0
1
2
3
4
5
1hr
MCP-1
0
5
10
20
F
o
l
d
c
h
a
n
g
e
F
o
l
d
c
h
a
n
g
e
F
o
l
d
c
h
a
n
g
e
4hrs
50
40
30
0
3
6
9
12
12hrs
Baseline GW9662 MK886
Baseline GW9662 MK886
Baseline GW9662 MK886
##
∗∗∗
∗∗∗
∗∗∗
∗∗
#
#
∗
(b)
Figure 2: Ligand-mediated regulation of PPAR transactivity altered Egr-1/MCP-1 mRNA levels. Downregulation of PPARα or γ by
pretreatment of RASMCs with 10μM MK886 or 1μM GW9662 followed by exposure to 10–50μM LA or OxLA for 1–12hrs resulted in
time-dependent induction of Egr-1 and MCP-1 mRNA levels as analyzed using qRT-PCR. Control-(CTRL-) vehicle only. mRNA levels were
expressed as fold change ± SEM (Standard error of ΔCT mean). (a) Egr-1 mRNA levels at 1, 4 and 12hrs; (b) MCP-1 mRNA levels at
1hr, 4 and 12hrs. One way ANOVA was used for comparison between two treatments. Signiﬁcance was conﬁrmed using Fisher LSD test.
∗compared to CTRL, #compared to 10μM concentration.
3.2. Ligand-Mediated Regulation of PPAR Transactivity Alters
Egr-1/MCP-1 mRNA Levels. ω-6 lipids and its oxidized
forms have dual eﬀects on vascular cells. Since these lipids
target both PPAR and Egr-1, we speculated that in the
absence of PPARs (either by antagonizing the receptor using
chemical antagonists or by siRNA approach), the ω-6 lipids
will be able to activate Egr-1 and proinﬂammatory eﬀects.
The results shown in Figure 2 indicate that in the presence
of a PPARα antagonist MK886, the ω-6 lipids, LA, and
OxLA had an immediate eﬀect (acute phase) on Egr-1 and
its downstream target MCP-1 mRNA levels. At 1 hour,
both lipids signiﬁcantly induced Egr-1 mRNA levels (3–20
fold) (Figures 2(a)-2(b)) but only had minimal eﬀect on
MCP-1 (1-2-fold), at all concentrations (10–50μML Aa n d
OxLA) tested, compared to vehicle CTRL. This induction
was further increased around 4hrs, when levels of Egr-1
(10–80-fold) and MCP-1 (5–45-fold) by LA and Ox-LA was
induced by 3–5 times higher than after 1hr treatment and
compared to vehicle CTRL. But around 12 hours, the Egr-
1/MCP-1 levels returned to near baseline levels. Minimal
eﬀects on Egr-1/MCP-1 were observed by the antagonists
themselves.6 PPAR Research
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Figure 3: PPAR mediated alteration in Egr-1/MCP-1 protein levels by ω-6 lipids. Egr-1 and MCP-1 protein levels were determined using
Western blot in cells exposed to ω-6 lipids after pretreatment with PPARα or γ antagonists, MK886 or GW9662. Control-(CTRL) vehicle
only. The results were expressed as mean ± SEM (Standard Error of Mean). (a–c) Egr-1 protein levels after 1, 4, and 12hrs; (d–f) MCP-1
proteinlevelsafter1,4,and12hrs.OnewayANOVAwasusedforthecomparisonbetweentwotreatments.Signiﬁcancewasconﬁrmedusing
post hoc Fisher LSD test. ∗P<0.05.
In contrast, in the presence of PPARγ antagonist
GW9662, the ω-6 lipids had a higher induction of Egr-1
and MCP-1 at a later time point, that is, 12 hours (subacute
phase) (Figures 2(a)-2(b)). There was a minimal or no
apparent induction of Egr-1 or MCP-1 at 1–4hrs at all
concentrations of LA and OxLA tested compared to vehicle
CTRL. However, after 12 hours, cells exposed to GW9662
exhibited enhanced induction of Egr-1 and MCP-1 (5–10-
fold) mRNA levels especially at higher concentrations of
OxLA [18 fold, 50μM] compared to vehicle CTRL.
3.3. PPAR-Mediated Alteration in Egr-1/MCP-1 Protein Levels
by ω-6 Lipids. Western blotting of the cell lysates obtained
fromtheabovetreatedcellsindicatedthatbothLAandOxLA
had similar trends on Egr-1 or MCP-1 protein levels as seen
with the mRNA levels. As shown in Figures 3(a)-3(b),a t1h r
and 4hrs (acute phase), LA and OxLA had minimal induc-
tion of Egr-1 protein. However, pretreatment with MK886
(PPARα antagonist) exhibited a slightly larger induction of
Egr-1 (2-fold). At 12hrs the baseline Egr-1 protein levels
were higher than that seen in the acute phase, however, when
c e l l sw e r ep r e t r e a t e dwi t hM K 8 8 6f o l l o w e db ye x p o s u r et oω-
6 lipids there was a downregulation of Egr-1 protein levels,
whereas pretreatment with GW9662, exhibited higher levels
of Egr-1 protein, in a concentration-dependent manner
(Figure 3(c)) compared to vehicle CTRL. This induction
reached signiﬁcance at 50μMO x L A( P<0.05).PPAR Research 7
Similar trends were observed with the Egr-1 downstream
target, MCP-1 protein levels in the presence of ω-6 lipids
(Figures 3(d)–3(f)). MK886 pretreatment had an initial
increase in MCP-1 levels at 4hrs followed by a return
to baseline levels at 12hrs, upon exposure to ω-6 lipids.
On the other hand, these lipids had minimal eﬀects on
MCP-1 protein levels when PPARγ was inhibited (GW9662
pretreated cells) at all time points tested except for the higher
doses of the OxLA at 12hrs.
3.4. siRNA-Mediated Downregulation of PPARs Modulated
Egr-1 Levels. The results above indicated that inhibition of
PPARs by antagonists modulated Egr-1 levels by ω-6 lipids.
In order to validate the above ﬁndings where PPARs were
downregulated by the use of antagonists and establish the
relationship between PPAR levels and Egr-1 modulation by
ω-6 lipids, in this experiment we used siRNA approach to
downregulate either PPARα or PPARγ in RASMCs followed
by treatment with diﬀerent concentrations of ω-6 lipids for
4o r1 2h r s .A ss h o w ni nFigure 4, our preliminary ﬁndings
indicated that compared to the concentration-dependent
Egr-1 induction by ω-6 lipids the nontargeting siRNA group,
the Egr-1 levels were upregulated by over 20–25-fold when
PPARα was downregulated by siRNA approach at 4hrs
compared to PPARγ downregulation. The eﬀects of ω-6
lipids were less apparent at the subacute phase. These initial
ﬁndings have similar trends in Egr-1 levels as observed in the
presence of PPAR antagonists.
3.5. Alterations in Egr-1/MCP-1 Levels by ω-6 Lipids Modu-
latesMonocyteAdhesiontoRASMCs. Monocyte/macrophage
inﬁltration into the subendothelial space of arteries is
an important step in the atherogenic process [48]. Egr-
1/MCP-1 interplay plays an important role in promoting
atherogenic lipids (OxLDLs) initiating monocyte inﬁltration
and adhesion during atherosclerosis [49–51]. Since, our
results thus far indicated that ω-6 lipids by regulating
PPAR transactivity were able to modulate Egr-1/MCP-1
mRNA and protein levels, we speculated that this will alter
monocyte adhesion to vascular cells in a time-dependent
fashion. Figures 5(a)-5(b) demonstrate that in the absence of
PPAR antagonists, ω-6 lipids had a concentration-dependent
increase in the number of monocytes adhered to RASMCs
(P< 0.05) at both 4 and 12hrs treatments. However,
in the presence of PPAR antagonists, these lipid ligands
had a PPAR-subtype-dependent modulation of monocyte
adhesion to RASMCs. Pretreatment with MK886 (PPARα
antagonist) signiﬁcantly increased monocyte adhesion by
PPAR lipid ligands at 4 hours, whereas PPARγ inhibition
(GW9662 treated) increased adhesion at a later time point
(12 hours) reﬂecting the increase in Egr-1/MCP-1 mRNA
and protein levels in the presence of these antagonists at
these respective time points. PPAR antagonists by themselves
did seem to have an eﬀect on the monocyte adhesion to
RASMCs, but the lipid treatments were in addition to what
was observed at baseline.
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Figure 4: Downregulation of PPARs by siRNA alters ω-6 lipid-
mediated induction of Egr-1 mRNA: RASMCs were transfected
with SMART-pool siRNA duplexes of PPARα,P P A R γ or nontar-
geting control siRNA, followed by treatment with ω-6 lipids for
4 and 12hrs. Preliminary ﬁndings indicated Egr-1 mRNA levels
were upregulated when PPARα was knocked down compared to
PPARγ knockdown as determined by qRT-PCR. The fold change
was calculated by comparing lipid treatments with vehicle controls
in each siRNA group. All values were normalized to β-actin (house-
keeping gene). mRNA levels were expressed as fold change ± SEM
(Standard error of ΔCT mean).
4. Discussion
Our study for the ﬁrst time demonstrates that atherogenic
ω-6 lipids, such as linoleic acid and its oxidized forms
(13-HPODE/13HODE), (abundant in diet and associated
with OxLDL) modulate PPAR/Egr-1 crosstalk, resulting in
altered vSMC function. In the presence of PPAR antagonists,
ω-6 lipids altered Egr-1-mediated responses through its
divergent eﬀe c to nP P A Rs u b t y p e si nat i m e - d e p e n d e n t
manner. Though our studies used these lipids in the free
form, in physiology these fatty acids are either part of
membrane lipids or major components of lipoproteins. We
predict that oxidation of most of the dietary lipids both
in the free form or in an esteriﬁed form will have similar
eﬀects. Depending on its dose and time of exposure, ω-6
lipids have biphasic eﬀects on vascular inﬂammation [51–
53]. vSMCs that make up the intimal and medial layer of
the vessel wall play an important role in the initiation and
early progression of atherosclerosis [54]. ω-6 lipids medi-
ate smooth muscle migration, proliferation, and apoptosis
during the atherosclerotic process [55]. These lipids have
multiple proinﬂammatory eﬀects on the vasculature which
include, activation of adhesion molecules, chemoattractants,
NFκB pathway, and activation of scavenger receptors leading
to foam cell formation [50, 56, 57]. On the other hand, we
and others have also shown anti-inﬂammatory eﬀects of ω-6
lipids, such as their ability to inhibit tumor necrosis alpha
(TNFα) production, inhibition of nitric oxide production,
and activation of antioxidant enzymes [53, 58–60].
Thezincﬁngertranscription factor,Egr-1, isexpressedin
all vascular cells including endothelial cells, smooth muscle8 PPAR Research
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Figure 5: Alterations in Egr-1/MCP-1 by ω-6 lipids resulted in altered monocyte (THP1) adhesion to RASMCs THP1 (human monocyte)
cells adhesion to RASMCs exposed to LA and OxLA (with or without pretreatment to MK886 and GW9662) was determined by counting
thenumber of cells in a 3 × 3 ﬁeld on an inverted ﬂuorescent microscope. Results showed that monocyte adhesion reﬂected the alterations in
Egr-1andMCP-1levelsbyω-6lipidsbyanincreaseinadherentmonocytecellnumberat4hrswhenPPARαwasdownregulatedandincrease
in adherent cell number at 12hrs when PPARγ was downregulated. The data presented represents mean numbers of THP1 cells adhered to
RASMCs in each ﬁeld ± SEM (Standard Error of Mean). (a) monocyte adhesion at 4hrs; (b) monocyte adhesion at 12hrs. ∗P< 0.05,
∗∗P< 0.01, ∗∗∗P< 0.005.
cells, and monocyte/macrophages [61]. Egr-1 is also upregu-
lated in the atherosclerotic ﬁbrous cap [62]. Oxidative stress,
an important player in atherosclerosis can induce Egr-1
[63,64]andconversely,deletionofEgr-1showedaprotective
eﬀect in the Apo E−/− atherosclerosis mouse model [65,
66]. Several factors including platelet-derived growth factor
[67, 68], ﬁbroblast growth factor [69], angiotensin-II [70],
and oxidative stress [71] activates Egr-1 in vascular tissues
including vascular smooth muscle cells [70]. A recent study
demonstrated that oxidants such as H2O2,a c t i v a t e dE g r - 1
in vascular smooth muscle cells in both a time- and dose-
dependent manner [64]. In the present study, in the presence
of PPAR antagonists, the ω-6 lipids had a biphasic eﬀect on
PPAR subtypes, an activation of PPARα in the acute phase
(1–4 hours), and PPARγ in the subacute phase (12 hours).
Themechanismbehindthisbiphasiceﬀectcanonlypresently
be speculated to be a probable regulation of PPAR turnover
by these lipids. ω-6 lipids are physiological ligands of PPARs
and biophysical studies conﬁrmed a covalent interaction
between these lipids with PPARs [29, 30]. These interactions
were diﬀerent from that seen with known PPAR synthetic
ligands that is, rosiglitazone or ﬁbrates. In the present study,
both from the preliminary PPAR siRNA ﬁndings and the
PPRE-luciferase transactivity studies in RASMCs, in the
presence of PPAR antagonists indicated that ω-6 lipids had
a higher induction of PPARα promoter compared to PPARγ,
however, we still observed that blocking PPARγ did enhance
Egr-1/MCP-1 in the subacute phase. This can probably be
attributed to increased generation of intracellular oxidative
stress including H2O2 [58, 72] at the subacute phase or
through the inhibition of Egr-1 by PPARγ [20, 23].
In both atherosclerotic and ischemic models, PPAR
ligandsareknowntoinhibitmultipleproinﬂammatorygenes
by inhibiting Egr-1 [20, 21, 73]. Our ﬁndings further showed
that the time-dependent eﬀect of OxLA on PPARs/Egr-1
crosstalk and the resultant alterations in Egr-1/MCP-1 levels
also resulted in altered smooth muscle cell chemoattrac-
tion to monocytes. Selective blocking of PPARα (MK886)
enhanced monocyte adhesion at 4hrs, whereas blocking of
PPARγ (GW9662) enhanced monocyte adhesion at 12hrs.
This data further supports the time-dependent paradoxical
eﬀects of OxLA during the atherogenesis process [50, 53,
59]. Since, pretreatment with MK886 exhibited a higher
inhibition of OxLA-induced PPRE transactivity but a higherPPAR Research 9
induction of Egr-1/MCP-1 and monocyte adhesion than
GW9662, it can be speculated that the ω-6 lipids seems
to have a predominant inﬂuence on PPARα compared to
PPARγ in vSMCs.
In the present studies, though both unoxidized and
oxidized linoleic acid exhibited similar regulatory eﬀects on
Egr-1/MCP-1 and PPAR levels, at similar concentrations,
OxLA had a more dramatic eﬀect than LA. Both unoxidized
and oxidized forms are ligands of PPARs and have been
shown to have similar vascular eﬀects. This may be explained
by (i) the ability of LA similar to OxLA to generate
reactive oxygen species (ROS), though at lower levels, by
mitochondrial oxidation [74] and fatty acid peroxisomal
degradation [75]. ROS generated through these pathways
induces transcription factors including NFκBa n dE g r - 1
[71, 76, 77]. (ii) Secondly, other than dietary and other
extracellular sources, the hydrolysis of esteriﬁed lipids by
intracellular lipoxygenase and cycloxygenase pathway can
also generate oxidized lipids [78, 79]f r o mL A .
Our results, to our knowledge, for the ﬁrst time demon-
strate that ω-6 lipids depending on the dose and time of
exposure on vascular cells have a preferential activation of
speciﬁc PPAR subtypes. Whether this preferential activation
of PPAR subtypes is reﬂective of the ability of these lipids
to modulate PPAR turnover is currently being investigated.
The interactions of these lipid ligands on both Egr-1 and
PPAR subtypes results in an altered crosstalk between Egr-1
and PPARs which ultimately reﬂected in altered atherogenic
response by the vascular cells (Scheme 1). Our results
provide novel insights into the regulatory role of dietary ω-
6 lipids on two of the major transcription factors that are
relevant to atherosclerosis, PPAR, and Egr-1 with diﬀering
vascular eﬀects.
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